How much sugar should be reduced to the ideal?

Diabetes, is its rising incidence trend, has become a serious threat to human health, the prevalence of diseases. According to the World Diabetes Federation 2007, published data show that China now has 39.8 million diabetics, is expected by 2025 will reach 59.3 million, of which 90% to 95% of type 2 diabetes; cardiovascular and cerebrovascular diseases, kidney and retina microvascular disease is the most common complications of type 2 diabetes is leading cause of death, cause of disability. Recalling the past, clinical research of diabetes, before the people are two urgent problems: type 2 diabetes blood sugar level should be down to how much? Whether the enhanced blood glucose control can reduce the vascular complications? Current treatment guidelines and the International Diabetes Federation Diabetes guidelines all recommend our type 2 diabetic patients should be glycosylated hemoglobin control to 6.5% or less, but this is mainly the result of speculation based on epidemiological data, the results confirm that there is no drug intervention, the medical sector In anticipation of new evidence-based strategies for clinical medical research to provide more solid evidence.

Beijing June 7, 2008, American Diabetes Association (ADA) 68th Annual Meeting from 20 countries, 11,140 cases of type 2 diabetes participated, so far the largest diabetes study - ADVANCE Study. Well-known New England Journal of Medicine also published the results of the study. ADVANCE study with cardiovascular risk factors for type 2 diabetes to reduce the glycated hemoglobin value of less than 6.5% as treatment goals, evaluating whether the enhanced blood glucose control can further reduce the variety of vascular complications. After 5 years of observation, the study confirmed to gliclazide sustained-release tablets (up to U.S. health tablets) enhanced glucose-based program to achieve a safe hypoglycemic compliance, a significant reduction in major vascular and microvascular Fuge end 10% risk, including cardiovascular death in the end, the most common diabetic incident, the diabetic complications, including kidney disease by up to 21%, albuminuria by 30%, which is a major reduction of cardiovascular death predictors. Meanwhile, the study of serious hypoglycemia was only UKPDS study of 1 / 3, which demonstrate the good safety of the treatment plan. Thus, patients from tablets to gliclazide enhanced glucose-based comprehensive benefit program.

ADVANCE study results for the development of future diabetes treatment strategies provide an important basis, therefore a milestone. Concern is that one-third of the study patients from China, China's diabetes strategy will no doubt provide a more adequate and convincing evidence. Latest from the Chinese Medical Association Diabetes credits will be issued by the Chinese type 2 diabetes prevention guidelines, specifically that control blood sugar in diabetic patients with glycated hemoglobin target is lower than 6.5%, which is the goal of ADVANCE glucose. Therefore, ADVANCE study used to gliclazide tablets based Intensive Glucose programs, safe and effective, worthy of further promotion.